Alberto Zanetto,Filippo Pelizzaro,Elena Bellan et al.
Alberto Zanetto et al.
At the dawn of potent therapeutics for fatty liver disease - introducing the miniseries on promising pharmacological targets for NASH [0.03%]
针对NASH的潜在药物靶点——前景治疗手段系列介绍之首篇
Vlad Ratziu,Frank Tacke
Vlad Ratziu
The fundamental importance of exploring the risks alongside the benefits of artificial intelligence [0.03%]
探索人工智能益处与风险的根本重要性
Philip Berry,Sreelakshmi Kotha
Philip Berry
A new era for steatotic liver disease: Evaluating the novel nomenclature in the UK Biobank [0.03%]
非酒精性脂肪肝疾病命名的变迁：英国生物银行的真实写照
Kai Markus Schneider,Carolin V Schneider
Kai Markus Schneider
Werner Klotz,Manfred Herold
Werner Klotz
Palliative clinical trials in advanced chronic liver disease: Challenges and opportunities [0.03%]
终末期肝病姑息治疗临床试验的挑战与机遇
Sumita Verma,Jay Hingwala,Joseph T S Low et al.
Sumita Verma et al.
Patients with advanced chronic liver disease have a complex symptom burden and many are not candidates for curative therapy. Despite this, provision of palliative interventions remains woefully inadequate, with an insufficient evidence base...
Which risk model can better predict hepatocellular carcinoma in hepatitis B patients with an antiviral treatment duration of over 1 year? [0.03%]
哪种风险模型能够更好地预测抗病毒治疗超过一年的乙肝患者肝细胞癌的发生？
Ming-Cheng Guan,Qian Ding,Hong Zhu
Ming-Cheng Guan
The protective association of HLA-B∗52:01, HLA-C∗12:02, and DQB1∗06:01 alleles with severe acute hepatitis of unknown origin in Japanese children [0.03%]
日本儿童不明原因重症急性肝炎的保护性HLA-B*52：01、HLA-C*12：02和DQB1*06：01等位基因关联研究
Tatsuya Okamoto,Hideaki Okajima,Eri Ogawa et al.
Tatsuya Okamoto et al.
Comment on "TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis" [0.03%]
"TIPS可防止肝硬化和门脉高压患者的进一步失代偿并提高其生存率——来自个体患者资料的meta分析的评论"
Lorenzo Ridola,Oliviero Riggio
Lorenzo Ridola
Hendrik Vilstrup,Peter Lykke Eriksen,Peter Ott
Hendrik Vilstrup